The weekly litigation news digest is live. Subscribe now

IP Verse

Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof - EP3782612

The patent EP3782612 was granted to Celgene on Nov 8, 2023. The application was originally filed on May 14, 2009 under application number EP20201143A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3782612

CELGENE
Application Number
EP20201143A
Filing Date
May 14, 2009
Status
Granted And Under Opposition
Oct 6, 2023
Publication Date
Nov 8, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Oral formulations of 5-azacytidine that release the drug substantially in the stomach and achieve high peak plasma concentrations, enabling effective treatment of hematological malignancies. These formulations achieve peak concentrations of at least 100 ng/mL and maintain therapeutic efficacy over 90 minutes, with a maximum plasma concentration of at least 200 ng/mL. The formulations are designed to release the drug in the stomach environment, where 5-azacytidine is primarily metabolized, and achieve this therapeutic window without enteric coating.

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKAug 8, 2024ELKINGTON AND FIFEADMISSIBLE
HOFFMANN EITLEAug 8, 2024-ADMISSIBLE
STADA ARZNEIMITTELAug 8, 2024KERNEBECKADMISSIBLE
TEVA PHARMACEUTICALSAug 8, 2024D YOUNGADMISSIBLE
HAMM & WITTKOPPJul 30, 2024-ADMISSIBLE

Patent Citations (37) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS20010990061
DESCRIPTIONUS20050213823
DESCRIPTIONUS20070698983
DESCRIPTIONUS20070849958
DESCRIPTIONUS20080029134
DESCRIPTIONUS20080045823
DESCRIPTIONWO2008US52124
DESCRIPTIONUS2002051820
DESCRIPTIONUS2003039688
DESCRIPTIONUS2003104053
DESCRIPTIONUS2003104062
DESCRIPTIONUS2004162263
DESCRIPTIONUS2008057086
DESCRIPTIONUS4810643
DESCRIPTIONUS4999291
DESCRIPTIONUS5229496
DESCRIPTIONUS5391485
DESCRIPTIONUS5393870
DESCRIPTIONUS5528823
DESCRIPTIONUS5580755
DESCRIPTIONUS7038038
DESCRIPTIONUS7189740
DESCRIPTIONWO2008092127
DESCRIPTIONWO2009042767
OPPOSITIONEP2299984
OPPOSITIONEP2695609
OPPOSITIONEP3692983
OPPOSITIONEP3782611
OPPOSITIONUS2004186065
OPPOSITIONUS2006074046
OPPOSITIONWO2004082618
OPPOSITIONWO2006034154
OPPOSITIONWO2008028193
OPPOSITIONWO2009139888
OPPOSITIONWO2011014541
SEARCHUS2004186065
SEARCHWO2008028193

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents